<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427944</url>
  </required_header>
  <id_info>
    <org_study_id>XYFY2016-KL001-02</org_study_id>
    <nct_id>NCT03427944</nct_id>
  </id_info>
  <brief_title>the Effect of Calcium Dobesilate on Non Dialysis Patients With CKD</brief_title>
  <official_title>the Effect of Calcium Dobesilate on Non Dialysis Patients With Chronic Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Xuzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the feasibility of calcium dobesilate in the treatment of microvascular injury
      provides new ideas and theoretical basis for the prevention and treatment of chronic renal
      failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The deterioration of renal function is closely related to microvascular damage, calcium
      dobesilate is known as microcirculation protective agent, the investigators will further
      study its effect of non dialysis patients with chronic renal failure and explore the
      feasibility of calcium dobesilate in treatment of renal microvascular injury, the
      investigators will provide new ideas and theoretical basis for the prevention and treatment
      of chronic renal failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glomerular filtration rate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>emission computed tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum creatinine</measure>
    <time_frame>up to 6 months</time_frame>
    <description>intravenous blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C</measure>
    <time_frame>up to 6 months</time_frame>
    <description>intravenous blood sampling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Calcium Dobesilate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcium dobesilate group was treated with calcium dobesilate (500mg, tid , po), its conservative treatment was the same as that of the conventional treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Treatment group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>conventional treatment group was treated with conventional conservative treatment of renal failure (low protein, low salt, low fat, low phosphorus diet, balance the internal environment; control blood pressure ; remove intestinal toxins etc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Dobesilate group</intervention_name>
    <description>Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.</description>
    <arm_group_label>Calcium Dobesilate group</arm_group_label>
    <other_name>Treatment group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional Treatment group</intervention_name>
    <description>Conventional treatment were used to treat patients with chronic renal failure.</description>
    <arm_group_label>Conventional Treatment group</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enroll the non dialysis patients with chronic renal failure hospitalized in the
             Department of Nephrology of the Affiliated Hospital of Xuzhou Medical University.

          -  According to the glomerular filtration rate, the patients who were not required to be
             dialysate were at CKD3-5 (GFR between 10 and 59ml/min).

        Exclusion Criteria:

          -  Exclude those patients with diabetes, cardiovascular disease, severe infection, shock,
             dehydration, abnormal liver function, received glucocorticoid therapy, surgery and
             emergency dialysis.

          -  Eliminate those patients with respiratory disease(such as chronic obstructive
             pulmonary disease, bronchiectasis, asthma), cardiovascular diseases(such as acute and
             chronic cardiac insufficiency), blood system diseases (such as aplastic anemia,
             nutritional anemia and polycythemia vera).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Sun, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Sun, MD</last_name>
    <phone>15862158578</phone>
    <email>sundong126@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Sun, MD</last_name>
      <phone>15862158578</phone>
      <email>sundong126@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Berthet P, Farine JC, Barras JP. Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy. Int J Clin Pract. 1999 Dec;53(8):631-6.</citation>
    <PMID>10692760</PMID>
  </reference>
  <reference>
    <citation>Tejerina T, Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol. 1998 Sep;31(3):357-60. Review.</citation>
    <PMID>9703201</PMID>
  </reference>
  <reference>
    <citation>Brunet J, Farine JC, Garay RP, Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol. 1998;12(2):205-12.</citation>
    <PMID>9565776</PMID>
  </reference>
  <reference>
    <citation>Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, Berta A, Garay RP. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol. 2001 Oct 5;428(2):277-86.</citation>
    <PMID>11675046</PMID>
  </reference>
  <reference>
    <citation>Brunet J, Farine JC, Garay RP, Hannaert P. Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. Eur J Pharmacol. 1998 Oct 9;358(3):213-20.</citation>
    <PMID>9822887</PMID>
  </reference>
  <reference>
    <citation>Padilla E, Ganado P, Sanz M, Zeini M, Ruiz E, Triviño A, Ramírez AI, Salazar JJ, Ramírez JM, Rojas B, Hoz Rd, Tejerina T. Calcium dobesilate attenuates vascular injury and the progression of diabetic retinopathy in streptozotocin-induced diabetic rats. Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):132-42.</citation>
    <PMID>15386814</PMID>
  </reference>
  <reference>
    <citation>Ruiz E, Lorente R, Tejerina T. Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Br J Pharmacol. 1997 Jun;121(4):711-6.</citation>
    <PMID>9208138</PMID>
  </reference>
  <reference>
    <citation>Lozovskaia EL, Kaplunskiĭ GD, Sapezhinskiĭ II. [Superoxide dismutase activity and photosensitizing properties of 2,5-dihydroxybenzolsulfonate]. Biofizika. 1990 Nov-Dec;35(6):912-6. Russian.</citation>
    <PMID>1965686</PMID>
  </reference>
  <reference>
    <citation>Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol. 2005;4(4):221-32.</citation>
    <PMID>16053339</PMID>
  </reference>
  <reference>
    <citation>Demirtas S, Caliskan A, Guclu O, Yazici S, Karahan O, Yavuz C, Mavitas B. Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis? Med Sci Monit Basic Res. 2013 Sep 27;19:253-7. doi: 10.12659/MSMBR.889427.</citation>
    <PMID>24072135</PMID>
  </reference>
  <reference>
    <citation>Larsen HW, Sander E, Hoppe R. The value of calcium dobesilate in the treatment of diabetic retinopathy. A controlled clinical trial. Diabetologia. 1977 Apr;13(2):105-9.</citation>
    <PMID>323093</PMID>
  </reference>
  <reference>
    <citation>Allain H, Ramelet AA, Polard E, Bentué-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf. 2004;27(9):649-60. Review.</citation>
    <PMID>15230646</PMID>
  </reference>
  <reference>
    <citation>Angulo J, Peiró C, Romacho T, Fernández A, Cuevas B, González-Corrochano R, Giménez-Gallego G, de Tejada IS, Sánchez-Ferrer CF, Cuevas P. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol. 2011 Sep 30;667(1-3):153-9. doi: 10.1016/j.ejphar.2011.06.015. Epub 2011 Jun 22.</citation>
    <PMID>21703259</PMID>
  </reference>
  <reference>
    <citation>Barr CC. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med 342:381-9, 2000. Surv Ophthalmol. 2001 Mar-Apr;45(5):459-60.</citation>
    <PMID>11274700</PMID>
  </reference>
  <reference>
    <citation>Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG; DX-Retinopathy Study Group. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1591-600.</citation>
    <PMID>16763797</PMID>
  </reference>
  <reference>
    <citation>Leal EC, Martins J, Voabil P, Liberal J, Chiavaroli C, Bauer J, Cunha-Vaz J, Ambrósio AF. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes. 2010 Oct;59(10):2637-45. doi: 10.2337/db09-1421. Epub 2010 Jul 13.</citation>
    <PMID>20627932</PMID>
  </reference>
  <reference>
    <citation>Velpandian T, Nirmal J, Gupta P, Vijayakumar AR, Ghose S. Evaluation of calcium dobesilate for its anti-cataract potential in experimental animal models. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):171-9. doi: 10.1358/mf.2010.32.3.1423888.</citation>
    <PMID>20448859</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>February 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcium Dobesilate</keyword>
  <keyword>Non Dialysis Patients With CKD(3-5)</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>serum creatinine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Dobesilate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

